Competitive-intel brief on a Phase II readout
Four agents turn a rival's trial data into a defensible brief.
Open the live lab · pre-loaded to this scenario
Multi-Agent Orchestration Board
Context
A pharma competitive-intelligence team must brief leadership on a rival's Phase II readout within 48 hours. A researcher pulls the trial registry, press, and KOL commentary; an analyst reconciles the reported endpoints against the label ambition; a medical writer drafts; and a regulatory critic checks every claim against what the data actually supports.
The decision
Multi-agent is worth the multiple only for high-stakes synthesis like this — where a wrong read moves a portfolio decision. Routine literature scans stay single-agent.
What most miss
The regulatory critic is the difference between 'intel' and 'a claim our own medical team can't defend.' Speed without the critic manufactures confident errors.
Stakes
A misread efficacy signal can misdirect a go/no-go on a program worth hundreds of millions.
Studied · Agent & Protocol · verified 2026-07-03
Sources: Clinical-trial reporting norms — ClinicalTrials.gov, Phase II endpoint conventions; Pharma competitive-intelligence workflow patterns (registry + KOL synthesis)